MorphoSys prepares for regulatory filings

MorphoSys AG is planning a regulatory filing in Europe for its first wholly-owned antibody therapeutic for cancer, tafasitamab, in addition to completing a rolling submission for the same drug with the US Food and Drug Admission. The plans for a marketing authorisation application to the European Medicines Agency were disclosed with the release of the company’s second quarter results and represent an acceleration of the commercialisation plans for tafasitamab, a treatment for refractory diffuse large B cell lymphoma.